Bipolar Disorder: Mood Stabilizers, Lithium Monitoring, and Acute Mania Management

Bipolar disorder is a chronic psychiatric condition characterized by recurrent episodes of mania/hypomania and major depression, affecting approximately 2.8% of adults in the United States. [KEY_CONCEPT] The disorder represents a spectrum of mood episodes with varying severity, duration, and functional impairment.

Epidemiology

• Lifetime prevalence: 2.8% for any bipolar spectrum disorder
• Gender distribution: Equal prevalence between males and females
• Age of onset: Typically late teens to early twenties
• Genetic heritability: 60-85%, with first-degree relatives having 5-10x increased risk

Pathophysiology

[HIGH_YIELD] The pathophysiology involves dysregulation of multiple neurotransmitter systems:

Neurotransmitter Systems

Neuroanatomical Changes

• Prefrontal cortex: Reduced gray matter volume affecting executive function
• Hippocampus: Structural changes associated with memory impairment
• Amygdala: Hyperactivation during mood episodes
• White matter: Decreased fractional anisotropy in connecting tracts

[CLINICAL_PEARL] Bipolar disorder involves both structural brain changes and functional network disruptions, explaining why mood stabilization requires long-term treatment targeting multiple neurotransmitter systems.

Manic Episodes (DSM-5-TR Criteria)

[KEY_CONCEPT] A manic episode requires ≥1 week of persistently elevated, expansive, or irritable mood plus ≥3 symptoms (4 if mood is only irritable):

Core Manic Symptoms (GSTPAID Mnemonic)

• Grandiosity or inflated self-esteem
• Sleep need decreased (feels rested after 2-3 hours)
• Talkativeness or pressure to keep talking
• Pleasurable activities with high potential for consequences
• Activity increase (goal-directed) or psychomotor agitation
• Ideas - flight of ideas or racing thoughts
• Distractibility

Hypomanic Episodes

• Same symptoms as mania but 4-6 days duration
• No marked impairment in social/occupational functioning
• No psychotic features
• Observable change in functioning that is uncharacteristic

Major Depressive Episodes

[HIGH_YIELD] Bipolar depression often presents with atypical features:

• Hypersomnia rather than insomnia
• Hyperphagia and carbohydrate craving
• Leaden paralysis (heavy feeling in arms/legs)
• Psychomotor retardation more prominent than agitation
• Earlier age of onset compared to unipolar depression

Mixed Episodes

• Criteria met for both manic and major depressive episodes
• Highest suicide risk among all mood states
• Often misdiagnosed as unipolar depression with agitation

[CLINICAL_PEARL] Mixed episodes carry the highest suicide risk because patients have the energy and impulsivity of mania combined with the hopelessness of depression. Always assess for mixed features when evaluating mood episodes.

Diagnostic Evaluation

[KEY_CONCEPT] Diagnosis requires comprehensive psychiatric assessment with collateral history from family/friends, as patients often lack insight during manic episodes.

Essential Components

1. Detailed mood episode history with timeline
2. Substance use assessment (especially stimulants, steroids)
3. Medical history for secondary causes
4. Family psychiatric history
5. Functional impairment assessment

Laboratory Workup Algorithm

Initial Evaluation: ├── Complete Blood Count (CBC) ├── Comprehensive Metabolic Panel (CMP) ├── Thyroid Function Tests (TSH, T3, T4) ├── Urinalysis and Toxicology Screen ├── Vitamin B12 and Folate levels └── Consider: Syphilis serology, HIV testing

If Indicated: ├── Brain MRI (first episode, atypical presentation) ├── EEG (if seizure history or altered consciousness) ├── Dexamethasone suppression test └── Autoimmune encephalitis panel

Differential Diagnosis Comparison

[HIGH_YIELD] Secondary mania should be considered in patients with:

• First manic episode >50 years old
• Neurological symptoms or cognitive impairment
• Rapid onset without clear precipitants
• Atypical presentation or treatment resistance

[CLINICAL_PEARL] Always obtain collateral history during diagnostic evaluation, as patients in manic episodes often minimize symptoms and overestimate their functioning.

Emergency Assessment & Stabilization

[KEY_CONCEPT] Acute mania management prioritizes safety, rapid symptom control, and prevention of complications.

Immediate Risk Assessment

• Suicidality (especially with mixed features)
• Homicidality or violence risk
• Psychotic symptoms with command hallucinations
• Medical complications (dehydration, exhaustion, hyperthermia)
• Substance use complications

Pharmacological Management Algorithm

Acute Mania Treatment:

1st Line Options (choose one): ├── Lithium (0.6-1.2 mEq/L) + Antipsychotic ├── Valproate (50-125 μg/mL) + Antipsychotic └── Antipsychotic Monotherapy (severe agitation)

Antipsychotic Options: ├── Olanzapine 10-20 mg/day ├── Risperidone 2-6 mg/day ├── Quetiapine 400-800 mg/day ├── Aripiprazole 15-30 mg/day └── Haloperidol 5-15 mg/day (if injection needed)

Adjunctive Options: ├── Lorazepam 1-2 mg q6h PRN (agitation) ├── Clonazepam 0.5-2 mg BID (sleep/anxiety) └── Consider ECT if medication-refractory

Mood Stabilizer Selection

[HIGH_YIELD] Rapid loading protocols:

• Valproate: 20-30 mg/kg/day divided BID-TID
• Lithium: Start 900-1200 mg/day, check level in 5 days

[CLINICAL_PEARL] Combination therapy (mood stabilizer + antipsychotic) is often more effective than monotherapy for acute mania and reduces time to symptom control.

Lithium Therapeutic Monitoring

[KEY_CONCEPT] Lithium has a narrow therapeutic window requiring systematic monitoring to ensure efficacy while preventing toxicity.

Therapeutic Levels & Timing

• Acute mania: 0.8-1.2 mEq/L
• Maintenance: 0.6-1.0 mEq/L
• Elderly patients: 0.4-0.8 mEq/L
• Sample timing: 12 hours post-dose (steady-state)

Monitoring Schedule

Lithium Toxicity Management

Toxicity Levels & Symptoms

Lithium Toxicity Spectrum:

Mild (1.2-1.5 mEq/L): ├── Nausea, vomiting ├── Diarrhea ├── Fine tremor └── Fatigue

Moderate (1.5-2.0 mEq/L): ├── Coarse tremor ├── Confusion ├── Slurred speech └── Ataxia

Severe (>2.0 mEq/L): ├── Altered consciousness ├── Seizures ├── Coma └── Cardiovascular collapse

Toxicity Risk Factors

• Dehydration (most common)
• Renal impairment
• Drug interactions (ACE inhibitors, NSAIDs, thiazides)
• Sodium restriction
• Fever/illness
• Elderly age

[HIGH_YIELD] Drug interactions increasing lithium levels:

• ACE inhibitors/ARBs: Reduce renal clearance
• NSAIDs: Decrease GFR and increase reabsorption
• Thiazide diuretics: Increase proximal tubule reabsorption
• Metronidazole: Reduces renal clearance

Emergency Management

1. Discontinue lithium immediately
2. IV hydration with normal saline
3. Electrolyte monitoring and correction
4. Hemodialysis if:
   • Level >4.0 mEq/L
   • Severe symptoms regardless of level
   • Renal failure
   • Cardiovascular instability

[CLINICAL_PEARL] Lithium levels may continue to rise for 24-48 hours after discontinuation due to redistribution from intracellular compartments. Monitor closely and consider dialysis early in severe cases.

Maintenance Treatment Strategies

[KEY_CONCEPT] Long-term management focuses on relapse prevention, functioning optimization, and side effect minimization.

Maintenance Medication Options

Long-term Complications

Lithium-Associated Complications

• Chronic kidney disease: 10-15% develop CKD stage 3+
• Hypothyroidism: 15-20% prevalence
• Hyperparathyroidism: 2-3% prevalence
• Nephrogenic diabetes insipidus: 10-40% develop polyuria
• Cardiac conduction defects: Rare but serious

Metabolic Complications (Antipsychotics)

• Weight gain: 7-30% of baseline weight
• Diabetes mellitus: 2-3x increased risk
• Dyslipidemia: Elevated triglycerides and cholesterol
• Cardiovascular disease: Increased morbidity/mortality

Monitoring Algorithm for Long-term Treatment

Annual Monitoring: ├── Comprehensive metabolic panel ├── Lipid profile ├── Hemoglobin A1c or glucose ├── Thyroid function tests ├── Weight and BMI ├── Blood pressure └── Waist circumference

Special Populations: ├── Pregnancy: Folic acid, high-resolution ultrasound ├── Elderly: More frequent monitoring, lower targets └── Renal disease: Nephrology consultation

[HIGH_YIELD] Pregnancy considerations:

• Lithium: Teratogenic (Ebstein anomaly), requires level monitoring
• Valproate: Category X, neural tube defects, cognitive impairment
• Carbamazepine: Neural tube defects, requires folate supplementation
• Lamotrigine: Relatively safer, may need dose adjustments

Suicide Prevention

[CLINICAL_PEARL] Bipolar disorder has one of the highest suicide rates among psychiatric conditions (15-20 times general population). Lithium specifically reduces suicide risk by 60-70%, independent of its mood-stabilizing effects.

Risk Factors for Suicide

• Mixed episodes or rapid cycling
• Comorbid substance use
• Previous suicide attempts
• Early age of onset
• Frequent hospitalizations
• Social isolation

[KEY_CONCEPT] Long-term lithium therapy provides neuroprotective effects and suicide prevention benefits that extend beyond mood stabilization, making it first-line treatment for many patients despite monitoring requirements.